|
Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in patients with metastatic soft-tissue sarcomas (mSTS). |
|
|
Consulting or Advisory Role - GenesisCare |
Research Funding - Merck KGaA (Inst) |
|
|
Honoraria - Amgen; Ethicon/Johnson & Johnson |
Consulting or Advisory Role - Boston Scientific |
|
Research Funding - Ethicon/Johnson & Johnson (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |